MedTrace Logo

Pharmacogenomics of Asparaginase Induced Hepatotoxicity

NCT03568266 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2025-12-04

No results posted yet for this study

Summary

This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.

Conditions

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of saliva

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Houda Alachkar, Ph.D. · University of Southern California

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-22
Primary Completion
2026-06-30
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03568266 on ClinicalTrials.gov